{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:28:27Z","timestamp":1784302107299,"version":"3.55.0"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,7,17]],"date-time":"2015-07-17T00:00:00Z","timestamp":1437091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"U.S. National Institutes of Health (NIH)","award":["U01AI069907"],"award-info":[{"award-number":["U01AI069907"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec><jats:label\/><jats:p>HIV drug resistance assessments and interpretations can be obtained from genotyping (GT), virtual phenotyping (VP) and laboratory\u2010based phenotyping (PT). We compared resistance calls obtained from GT and VP with those from PT (GT\u2010PT and VP\u2010PT) among CRF01_AE and subtype B HIV\u20101 infected patients. GT predictions were obtained from the Stanford HIV database. VP and PT were obtained from Janssen Diagnostics BVBA's vircoType<jats:sup>TM<\/jats:sup> HIV\u20101 and Antivirogram\u00ae, respectively. With PT assumed as the \u201cgold standard,\u201d the area under the curve (AUC) and the Bland\u2013Altman plot were used to assess the level of agreement in resistance interpretations. A total of 80 CRF01_AE samples from Asia and 100 subtype B from Janssen Diagnostics BVBA's database were analysed. CRF01_AE showed discordances ranging from 3 to 27 samples for GT\u2010PT and 1 to 20 samples for VP\u2010PT. The GT\u2010PT and VP\u2010PT AUCs were 0.76\u20130.97 and 0.81\u20130.99, respectively. Subtype B showed 3\u201361 discordances for GT\u2010PT and 2\u201375 discordances for VP\u2010PT. The AUCs ranged from 0.55 to 0.95 for GT\u2010PT and 0.55 to 0.97 for VP\u2010PT. Didanosine had the highest proportion of discordances and\/or AUC in all comparisons. The patient with the largest didanosine FC difference in each subtype harboured Q151M mutation. Overall, GT and VP predictions for CRF01_AE performed significantly better than subtype B for three NRTIs. Although discrepancies exist, GT and VP resistance interpretations in HIV\u20101 CRF01_AE strains were highly robust in comparison with the gold\u2010standard PT. <jats:bold><jats:italic>J. Med. Virol. 88:234\u2013243, 2016<\/jats:italic>.<\/jats:bold> \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jmv.24320","type":"journal-article","created":{"date-parts":[[2015,7,4]],"date-time":"2015-07-04T01:53:18Z","timestamp":1435974798000},"page":"234-243","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory\u2010based phenotypes among CRF01_AE and subtype B HIV\u2010infected individuals"],"prefix":"10.1002","volume":"88","author":[{"given":"Awachana","family":"Jiamsakul","sequence":"first","affiliation":[{"name":"The Kirby Institute UNSW Australia Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romanee","family":"Chaiwarith","sequence":"additional","affiliation":[{"name":"Research Institute for Health Sciences Chiang Mai University Chiang Mai Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Durier","sequence":"additional","affiliation":[{"name":"TREAT Asia amfAR \u2010 The Foundation for AIDS Research Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunee","family":"Sirivichayakul","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Chulalongkorn University and HIV\u2010NAT\/Thai Red Cross AIDS Research Centre Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasisopin","family":"Kiertiburanakul","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Van Den Eede","sequence":"additional","affiliation":[{"name":"Janssen Diagnostics BVBA Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Ditangco","sequence":"additional","affiliation":[{"name":"Research Institute for Tropical Medicine Manila Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeeba","family":"Kamarulzaman","sequence":"additional","affiliation":[{"name":"University of Malaya Medical Center Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick CK","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicine Queen Elizabeth Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winai","family":"Ratanasuwan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thira","family":"Sirisanthana","sequence":"additional","affiliation":[{"name":"Research Institute for Health Sciences Chiang Mai University Chiang Mai Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the TREAT Asia Studies to Evaluate Resistance\u2014Monitoring Study TASER\u2010M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2307\/2987937"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu666"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004724"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90837-8"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyq192"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328342ff93"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-5-582"},{"key":"e_1_2_7_9_1","first-page":"6","article-title":"Update of the drug resistance mutations in HIV\u20101: March 2013","volume":"21","author":"Johnson VA","year":"2013","journal-title":"Top Antivi Med"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f5ff71"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1086\/503914"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.06.014"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073744"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000332013"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2008.03.017"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/157016212803901356"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg100"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq130"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1086\/505356"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.694-701.2006"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-7-38"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00611-11"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir107"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir107"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2011.011337"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/11633630-000000000-00000"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21585"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.2005.00011.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2007.05.009"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.11.010"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.24320","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.24320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T08:28:38Z","timestamp":1696321718000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.24320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,17]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1002\/jmv.24320"],"URL":"https:\/\/doi.org\/10.1002\/jmv.24320","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,17]]}}}